Muscle Disease Biomarker
Muscle Disease Biomarker - Related Videos
09:00
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
0 Views •
Cited by 14 •
2012
High throughput validation of multiple candidate biomarkers can be performed by sequential ELISA in order to minimize freeze/thaw cycles and use of precious plasma samples. Here, we demonstrate how to sequentially perform ELISAs for six different validated plasma biomarkers1-3 of graft-versus-host disease (GVHD)4 on the same plasma sample.
09:30
Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
0 Views •
Cited by 8 •
2016
Neuromuscular diseases often exhibit a temporally varying, spatially heterogeneous, and multi-faceted pathology. The goal of this protocol is to characterize this pathology using non-invasive magnetic resonance imaging methods.
05:58
Tissue Triage and Freezing for Models of Skeletal Muscle Disease
0 Views •
Cited by 98 •
2014
The analysis of skeletal muscle tissues to determine structural, functional, and biochemical properties is greatly facilitated by appropriate preparation. This protocol describes appropriate methods to prepare skeletal muscle tissue for a broad range of phenotyping studies.
06:09
Breath Collection from Children for Disease Biomarker Discovery
0 Views •
Cited by 11 •
2019
This protocol describes a simple method for the acquisition of breath samples from children. Briefly, samples of mixed air are pre-concentrated in sorbent tubes prior to gas chromatography-mass spectrometry analysis. Breath biomarkers of infectious and non-infectious diseases can be identified using this breath collection method.
07:58
Examining Muscle Regeneration in Zebrafish Models of Muscle Disease
0 Views •
Cited by 10 •
2021
Skeletal muscle regeneration is driven by tissue resident muscle stem cells, which are impaired in many muscle diseases such as muscular dystrophy, and this results in the inability of muscle to regenerate. Here, we describe a protocol that allows the examination of muscle regeneration in zebrafish models of muscle disease.
FAQs
Creatine kinase and myoglobin can enter the bloodstream when muscle fibers are damaged, creating measurable signals of cellular injury. Their concentrations therefore provide biological evidence that muscle tissue has been affected, although the broader interpretation depends on the disease process being studied. In research, these measurements help connect tissue damage with disease severity or progression.
A marker associated with fiber injury does not provide the same information as one reflecting inflammation, degeneration, or altered gene and protein activity. These categories represent different biological events within affected muscle. Selecting markers from the relevant category can help researchers distinguish disease features and support more informative classification than relying on a single measurement.
Each biomarker type can capture a different aspect of muscle disease. Circulating measurements provide laboratory-detectable signals, imaging can contribute complementary information about muscle, and molecular markers can reflect changes in gene or protein activity. Combining these sources may produce a more comprehensive assessment, improving understanding of disease mechanisms and supporting more precise patient evaluation.
Researchers can measure circulating markers such as creatine kinase and myoglobin with laboratory assays, while imaging and molecular approaches provide additional biological information. The selected measurements depend on whether the study focuses on muscle injury, inflammation, degeneration, or altered gene and protein activity. Using several approaches allows investigators to compare distinct disease-related signals.
Muscle disease biomarkers are useful when researchers need measurable indicators for monitoring how a disorder changes during treatment. Changes in relevant signals can be compared with disease status to assess response, while the same framework can support evaluation of emerging therapies. Their value lies in providing biological outcomes alongside broader assessments of disease progression.
Measurements such as circulating creatine kinase or myoglobin can contribute evidence of muscle injury, while imaging and molecular signals may add information about other disease features. Together, these data can help classify disorders, estimate severity, and track progression. In biology and clinical research, this supports more detailed comparisons among disease states and therapeutic outcomes.